drain contacts

PATENT ABSTRACTS A process for producing L-lysine, which comprises culturing a mutant L-lysine-producing strain belonging to the genus Brevibacterium or the genus Corynebacterium and having selenalysine resistance in a nutrient medium, producing and accumulating L-lysine in the culture broth and collecting L-lysine from the culture broth.

79

5362660 M E T H O D OF MAKING A THIN FILM T R A N S I S T O R S T R U C T U R E WITH IlVIPROVED S O U R C E / D R A I N CONTACTS Kwasnick Robert; Possin George E; Holden David E; Saia Richard J - General Electric Company

5362638 F U N G A L STRAINS AND USE T H E R E O F IN ANTIBIOTIC PRODUCTION Dahiya Jagroop Lovastatin is produced by a process of fermentation using a fungal transformant produced by introducing into a non-lovastatin expressing Aspergillus strain such as a strain of Aspergillus oryzae the DNA of a lovastatinexpressing strain of Aspergillus terreus

5362644 H Y B R I D PROTEINS B E T W E E N AN E X T R A C Y T O P L A S M I C E N Z Y M E A N D AT LEAST A N O T H E R PROTEIN, M E T H O D FOR P R E P A R I N G T H E M A N D ALSO T H E I R A P P L I C A T I O N S Boquet Paul; Boulain Jean-Claud; Frederic; Gillet Daniel; Menez Commissariat a I'Energie Atomique

Ducancel Andre

The disclosed invention involves a DNA encoding a hybrid tripartite protein comprising an amino portion consisting of from 6 to 28 amino acid residues from the N-terminal of a mature E. coli alkaline phosphatase, a central portion corresponding to a heterologous polypeptide and a carboxyl portion which consists of the remainder of the mature E. coli alkaline phosphatase, a different alkaline phosphatase or an enzymatically active fragment of either. The tripartite proteins produced with this DNA can be used as a diagnostic reagent and in the screening of nucleic acid libraries or in the selection of recombinant clones.

Minimum line spacing is reduced and line spacing uniformity is increased in thin film transistors by employing source/drain metallization having a first relatively thin layer of a first conductor and a second relatively thick layer of a second conductor. The second conductor is selected to be one which may be preferentially etched in the presence of the first conductor whereby the first conductor acts as an etch stop for the etchant used to pattern the second conductor portion of the source/drain metallization. This etching is preferably done using dry etching. Dry etching typically provides substantially better control of line width than wet etching. The etching of the second conductor can be done with a dry etch process which etches the photoresist at substantially the same rate as the second conductor whereby the second conductor is provided with a sidewall slope of substantially 45 degrees which improves the quality of passivation provided by subsequent deposition of a conformal passivating layer.

5362853 P O L Y P E P T I D E DERIVATIVES OF HUMAN GRANULOCYTE C O L O N Y STUVlULATING FACTOR Kuga Tetsuro; Miyaji Hiromas; Sato Moriyuki; Okabe Masami; Morimoto Makot; Itoh Seiga; Yamasaki Motto; Yokoo Yoshihar; Yamaguchi Kazu; Komatsu Yoshinor - Kyowa Hakko Kogyo Co Ltd Novel hG-CSF polypeptide derivatives having an amino acid sequence derived fromthe amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least one amino acid by a different amino acid and/or deletion of at least one amino acid, recombinant plasmids containing a DNA fragment insert coding for any of these hG-CSF polypeptide derivatives, microorganisms carrying one of such